Vietnam Medical and Pharmaceutical Investment Joint Stock Company (JVC) Fair Value & Analysis
Healthcare · VN · Market cap 371B VND
Fair value as of: Jul 11, 2026
From 13 valuation models · updated 30 days ago
Share price −7.3% over the past month.
A solid business, screening 111% undervalued on our models.
What matters now
- The price is below even our cautious bear case (5,135 VND). The market is more pessimistic than our downside scenario.
- Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 11, 2026.
How to read this chart
60‑month range 2,310 VND – 13,450 VND · fair‑value band 5,135 VND – 7,773 VND · the 3,060 VND price screens below the 6,454 VND fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 11, 2026.
Analysis
Vietnam Medical and Pharmaceutical Investment Joint Stock Company (JVC) currently trades at 3,060 VND, while our model-based Fair Value estimate is 6,454 VND, implying the stock looks roughly 110.9% undervalued today. The Quality Score stands at 50/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Vietnam Medical and Pharmaceutical Investment Joint Stock Company generated revenue of 741B VND at a net margin of 5.0%. Revenue declined 12.2% year over year. It earns a return on equity of 6.0%. Fundamentals as of Jul 11, 2026
Our scenario range runs from 5,135 VND (bear case) to 7,773 VND (bull case); at 3,060 VND, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 66% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at 111%, JVC screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 13 models by family
Widest divergence: Dividend Discount (2,609 VND) versus Multiples (2,419 VND). Highest evidence: Growth DCF (72).
Notify me when JVC reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 22
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Vietnam Medical and Pharmaceutical Investment Joint Stock Company engages in the distribution of medical equipment and instruments in Vietnam.
Full company description
Vietnam Medical and Pharmaceutical Investment Joint Stock Company engages in the distribution of medical equipment and instruments in Vietnam. The company distributes medical equipment, including diagnostic imaging products, such as magnetic resonance imaging (MRI), computed tomography (CT), X-ray system, computed and direct radiography, dry imager, contrast injector, PET/CT imaging system, and diagnostic ultrasound products; washers, dryers, and sterilizers; and ultrasound systems, anesthesia and breathing machines, syringe and infusion pumps, and patient monitors, as well as navigation products. It also offers SD-S, DI-HT, SD-Q, and DI-HL dry medical films; central venous catheters and invasive blood pressure transducers for resuscitation-cardiovascular intervention; Scepter XC and C balloon, and Chaperon guiding catheters; LVIS Jr. and LVIS coil assist stents; and V-grip detachment controllers, Traxcess guidewires, Headway Duo microcatheters, ERIC retrieval devices, SOFIA PLUS aspiration and SOFIA intermediate catheters, FRED and FRED Jr. flow diversion devices, platinum and hydrogel coils, PHIL liquid embolics, and Headway microcatheters. In addition, the company provides technical services, such as consulting, technical support, repair, and maintenance services; and IT services for hospitals. Further, it leases medical equipment and instruments; operates general, specialist, and dental clinics; invests in medical equipment; and engages in the financial investment activities. Vietnam Medical and Pharmaceutical Investment Joint Stock Company was formerly known as Japan Vietnam Medical Investment and Development Joint Stock Company and changed its name to Vietnam Medical and Pharmaceutical Investment Joint Stock Company in November 2025. The company was founded in 2001 and is headquartered in Hanoi, Vietnam.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2022 · reported fiscal years
Vietnam Medical and Pharmaceutical Investment Joint Stock Company reported revenue of 391B VND in FY2022 versus 517B VND in FY2020, a compound −13.0%/yr. Reported net income was −29.9B VND in FY2022.
Watch JVC: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare Vietnam Medical and Pharmaceutical Investment Joint Stock Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Vietnam Medical and Pharmaceutical Investment Joint Stock Company (JVC) overvalued or undervalued?
What is the fair value of JVC?
What is the quality score of JVC?
What is the revenue of Vietnam Medical and Pharmaceutical Investment Joint Stock Company (JVC)?
What is the net profit margin of JVC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Vietnam Medical and Pharmaceutical Investment Joint Stock Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.